Nimotuzumab plus paclitaxel for recurring stomach cancer
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial tests whether adding nimotuzumab (an anti-EGFR antibody) to paclitaxel can improve outcomes for people with stomach or stomach-junction cancer that has returned and spread. It targets tumors with high EGFR (“EGFR high” on a pathology test) to see if this combination works better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 75, and can be male or female
- Your performance status (ECOG) is 0 to 1, meaning you can do daily activities with little or some limits
- Your cancer is confirmed as gastric or esophagogastric-junction adenocarcinoma
- Your cancer is recurrent and metastatic, and you already had standard first treatment (or anti-HER2 therapy, or immunotherapy) or it progressed
- Your tumor sample tests “EGFR high” (IHC2+ or IHC3+) and you have at least one measurable tumor spot
- You have enough blood counts and organ function, and an estimated survival of at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs to treat stomach or junction cancer that has spread or come back after initial immunotherapy treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This study tests a new combination of drugs for advanced esophageal cancer. It adds an antibody (nimotuzumab) and an immunotherapy (sintilimab) to standard chemotherapy, aiming to improve how well treatment works.
This trial tests a combination of two drugs (nimotuzumab and tislelizumab) plus radiation for women whose cervical cancer has come back or spread to a few places in the body. The goal is to see if this treatment can shrink tumors and help patients live longer.
This trial tests a new drug combination (ivonescimab plus paclitaxel) as a second treatment for advanced stomach cancer. It's for people whose cancer grew after first-line therapy with a checkpoint inhibitor plus platinum-based chemotherapy.
This trial tests combining nimotuzumab with chemotherapy (nab-paclitaxel and gemcitabine) after surgery to prevent pancreatic cancer from returning. It is for people whose tumors have a protein called EGFR, and whose cancer was removed with clear or close margins.
This trial tests a three-drug combination (anlotinib, TQB2450, and nab-paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has progressed after prior treatment with a CLDN18.2-targeted regimen. The goal is to see if this new combination can shrink tumors and help patients live longer.
Hear when a new Gastric or Esophagogastric Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.